CharityAnnHuangMD

Oncology • Torrance, CA

Breast Cancer

Faculty

Join to view full profile

Dr. Huang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Huang's full profile

Already have an account?

Office
1000 W Carson St
# N18
Torrance, CA 90502
Phone+1 310-222-2345

Summary

Dr. Charity Huang is an oncologist specializing in breast cancer, based in Torrance, CA. She completed her fellowship in Hematology and Medical Oncology at the University of California (San Francisco)/Fresno in 2022, following her residency in Internal Medicine at HCA Healthcare Riverside. She graduated from the American University of the Caribbean School of Medicine in 2015. Dr. Huang is currently a faculty member at Harbor-UCLA Medical Center and has published research on thrombosis development post-mRNA COVID-19 vaccine administration and oxaliplatin-associated digital ischemia. Additionally, she is involved in clinical trials focused on breast cancer, lung cancer, melanoma, and RET-altered malignancies.

Education & Training

University of California (San Francisco)/FresnoFellowship, Hematology and Medical Oncology, 2019 - 2022
HCA Healthcare RiversideResidency, Internal Medicine, 2016 - 2019
American University of the Caribbean School of MedicineClass of 2015

Certifications & Licensure

CA State Medical License 2018 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2021 Dec 20
Recruiting
Phase 3
BESPOKE Study of ctDNA Guided Immunotherapy Start of enrollment: 2021 May 28
Active, not recruiting
A Study of EP0031 in Patients With Advanced RET-altered Malignancies Start of enrollment: 2022 Sep 30
Recruiting
Phase 1, Phase 2
CemiplimAb Survivorship Epidemiology Start of enrollment: 2019 Jun 27
Active, not recruiting
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer Start of enrollment: 2022 Mar 07
Recruiting
Phase 3
A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C Start of enrollment: 2023 Dec 21
Recruiting
Phase 3
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) Start of enrollment: 2023 Dec 11
Recruiting
Phase 3
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment Start of enrollment: 2024 Jan 09
Recruiting
Phase 3
A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma Start of enrollment: 2023 Jul 26
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

6 citations
Thrombosis Development After mRNA COVID-19 Vaccine Administration: A Case Series.
Sundeep Bekal, George Husari, Marcel Okura, Charity A Huang, Mohammed S Bukari
Cureus. 2023-07-01
1 citations
Digital ischaemia and necrosis from oxaliplatin.
Charity Huang, Leslie Storey, Uzair Chaudhary
BMJ Case Reports. 2022-02-07